Skip to main content

Multiple Myeloma

Multiple Myeloma Year in Review Introduction

Updates from the Phase 3 ICARIA-MM Study of Isatuximab plus Pomalidomide/Low-Dose Dexamethasone versus Pomalidomide/Low-Dose Dexamethasone in RRMM

COVID-19 Vaccine Responsiveness in Patients with MM and Waldenström Macroglobulinemia

Iberdomide plus Dexamethasone and Daratumumab, Bortezomib, or Carfilzomib in Patients with RRMM

CARDAMON Trial Results of Carfilzomib Maintenance Following Transplantation or Carfilzomib/Cyclophosphamide/Dexamethasone Consolidation for NDMM

MAIA Trial Results of Daratumumab, Lenalidomide, and Dexamethasone versus Lenalidomide and Dexamethasone in NDMM

Updated Results from CARTITUDE-2 Trial of Ciltacabtagene Autoleucel in Lenalidomide-Refractory Patients with Progressive MM After 1 to 3 Previous Lines of Therapy

Results of the Phase 3 GMMG-HD7 Trial of Isatuximab plus Lenalidomide, Bortezomib, and Dexamethasone as Induction Therapy for Transplant-Eligible NDMM

International Myeloma Working Group Recommendations for the Treatment of Patients with RRMM

Longer-Term Outcomes with Single-Agent Belantamab Mafodotin in Patients with RRMM: 13-Month Follow-Up from the Pivotal DREAMM-2 Study

2
3
4
5
6
7
8

Page 5 of 11
Results 41 - 50 of 104